On a cohort of 360 patients with advanced NSCLC, Xu et al. showed that the expression of EZH2 in biopsy samples predicts both chemoresistance to cisplatin-based chemotherapy (EZH2-negative patients respond better to chemotherapy) and survival (positive EZH2 expression was correlated with poor survival) [113]. This evidence concerns the gene EZH2 and non-small cell lung carcinoma.